Abstract 581P
Background
Although colorectal cancer (CRC) survivors often suffer from defecation related symptoms (DRS), there are very few treatment options to improve DRS. Strengthening of abdominal muscles to increase intra-abdominal pressure and pelvic floor exercises to improve pelvic floor dyssynergia may improve DRS in colorectal cancer patients. However, the effects of exercise on DRS have not been studied fully. Therefore, the purpose of this study is to investigate the efficacy of exercise on DRS in CRC.
Methods
A total of 120 CRC who completed surgery and adjuvants therapy were recruited out of 441 approached. 120 participants were randomly assigned to either exercise (EG) or usual care group (CG). The combined weekly supervised and home-based exercise program (12 weeks) includes increase in physical activity (PA) levels to meet the ACSM guideline as well as daily calisthenics exercises. Calisthenics exercises include a total of 12 movements aimed to increase whole body muscle strengths which focused on core and pelvic floor muscles. The primary outcome was DRS score assessed the sum of blood and mucus in stool, stool frequency, abdominal pain, buttock pain, bloating, flatulence, fecal incontinence and embarrassment in EOTRC-QLQ-CR29. A two-way ANOVA repeated measures were used determine group and time interaction. Table: 581P
Effects of exercise on defecatory symptoms
Control | Exercise | p-value | |||
Pre | Post | Pre | Post | ||
Blood in stool | 4.7 ± 9.7 | 4.4 ± 9.1 | 7.2 ± 15.5 | 3.1 ± 8.9 | 0.05 |
Stool frequency | 26.3 ± 27.0 | 20.1 ± 20.5 | 28.7 ± 25.1 | 23.4 ± 23.8 | 0.91 |
Abdominal pain | 14.4 ± 22.4 | 11.7 ± 19.2 | 18.3 ± 24.9 | 10.0 ± 16.6 | 0.21 |
Buttock pain | 12.2 ± 21.2 | 12.8 ± 25.4 | 18.9 ± 30.3 | 12.8 ± 26.1 | 0.08 |
Bloating | 22.8 ± 22.5 | 25.0 ± 25.8 | 34.4 ± 30.7 | 22.8 ± 27.1 | 0.01 |
Flatulence | 21.0 ± 26.0 | 17.7 ± 23.3 | 28.3 ± 33.5 | 21.5 ± 25.1 | 0.42 |
Fecal incontinence | 13.5 ± 20.5 | 13.1 ± 20.5 | 16.9 ± 24.8 | 12.9 ± 25.3 | 0.26 |
Embarrassment | 20.4 ± 26.8 | 16.7 ± 20.8 | 27.6 ± 32.0 | 18.0 ± 25.5 | 0.16 |
Bolds were statistically significant different between pre and post (p<.05), p= Difference between control vs. exercise
Results
Among the 120 participants enrolled, 100 (96.6%) completed the trial with supervised exercise compliance rate of 95%. PA levels increased and fitness levels improved only in the exercise group. Exercise significantly decreased DRS score (6 week - 0 week: CG= -14.0 ± 54.7 vs. EG= - 56.1 ± 99.5, p for group and time interaction = 0.02). Symptom scores in EG include blood and mucus in stool, abdominal pain, buttock pain, bloating, flatulence and embarrassment were improved.
Conclusions
It is concluded that both combined supervised and home-based exercise significantly reduced bowel and defecatory problems in colorectal cancer patients.
Clinical trial identification
This study was approved by The Institutional Review Board of Severance Hospital (IRB No. 4-2018-0841).
Editorial acknowledgement
This study was funded by the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA16C0012020020) and Yonsei Signature Research Cluster Program of 2021-22-0009.
Legal entity responsible for the study
The authors.
Funding
The National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea, Yonsei Signature Research Cluster Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10